Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18363119 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL15335166 | 0.76 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL22686382 | 0.74 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL15334892 | 0.74 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL20006074 | 0.73 | ALDH1A1 (0.32) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL11581015 | 0.71 | KDM4E (0.42) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL8149192 | 0.71 | ALDH1A1 (0.62) | ALDH1A1KDM4EMEN1USP2LMNA | |
| Nibrozetone SCHEMBL2249018 | 0.70 | NLRP3 (0.47) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL9918122 | 0.67 | APEX1 (0.46) | ALDH1A1 | |
| SCHEMBL21765684 | 0.67 | ALDH1A1 (0.50) | ALDH1A1KDM4EMEN1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215229-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONARY HYPERTENSION | EPICENTRX, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-11008287-B2 | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine | EPICENTRX, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200157047-A1 | SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOUNDS FOR USE IN MEDICINE | EPICENTRX, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008287-B2 | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine | AS3MT, SLC10A6, SLCO1B3 | ALDH1A1 2681/4885KDM4E 2187/4885MEN1 295/4885 |
| US-20200157047-A1 | SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOUNDS FOR USE IN MEDICINE | AS3MT, SLC10A6, SLCO1B3 | ALDH1A1 2681/4885KDM4E 2187/4885MEN1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.